| Id: | acc4733 |
| Group: | 1sens |
| Protein: | ERK |
| Gene Symbol: | Mapk3 |
| Protein Id: | P21708 |
| Protein Name: | MK03_RAT |
| PTM: | phosphorylation |
| Site: | Thr202 |
| Site Sequence: | DPEHDHTGFLTEYVATRWYRA |
| Disease Category: | Digestive system diseases |
| Disease: | Colonic Hypersensitivity |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | linaclotide |
| Drug Info: | Linaclotide is a medication used for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| Effect: | modulate |
| Effect Info: | Drugs inhibit stress-induced colonic hypersensitivity and ERK phosphorylation |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 33373484 |
| Sentence Index: | 33373484_11 |
| Sentence: | "GC-C agonism attenuated stress-induced colonic hypersensitivity and ERK phosphorylation, but had no effect on CRF expression, suggesting the analgesic effects of linaclotide occur independent of stress-driven CRF gene expression in corticolimbic circuitry." |
Sequence & Structure:
MAAAAAAPGGGGGEPRGTAGVVPVVPGEVEVVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRAPTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFDMELDDLPKERLKELIFQETARFQPGAPEAP
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 203 | D | Major depressive disorder | Phosphorylation | 16959794 |
| Y | 205 | D | Major depressive disorder | Phosphorylation | 16959794 |
| T | 203 | U | Uteroplacental insufficiency | Phosphorylation | 16940436 |
| Y | 205 | U | Uteroplacental insufficiency | Phosphorylation | 16940436 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
